Healthcare / BiotechnologyStockholm
$1.78
-0.03 (-1.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-260.9M · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$678M
P/E
N/A
•EV/EBITDA
N/A
•ROE
423.8%
↑Gross Margin
96.6%
↑Debt/Equity
-2.37
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+104.2%
FCF CAGR
—
FCF margin
-313.4%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $71.1M · net income $-249.6M · FCF $-222.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $71.1M | $71.1M | $31.6M | $35.2M | $8.4M |
| Net Income | $-249.6M | $-249.6M | $-284.6M | $-249.1M | $-338.0M |
| EBITDA | $-224.1M | $-224.1M | $-261.8M | $-231.6M | $-319.6M |
| EPS | -1.04 | -1.04 | -1.61 | -2.45 | -2.61 |
| Gross Margin | 96.6% | 96.6% | 91.6% | 103.1% | 99.9% |
| Operating Margin | -317.6% | -317.6% | -898.9% | -722.7% | -4214.7% |
| Net Margin | -350.9% | -350.9% | -899.3% | -707.3% | -4044.9% |
| Balance Sheet | |||||
| Debt/Equity | -2.37 | -2.37 | 2.61 | 2.31 | 0.03 |
| Current Ratio | 4.55 | 4.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-222.9M | $-222.9M | $-260.9M | $-279.6M | $-423.0M |
| Returns | |||||
| ROE | 423.8% | 423.8% | -524.3% | -438.7% | -114.8% |
| Valuation | |||||
| P/B | — | — | 5.10 | 13.78 | 5.36 |
| Growth & Yield | |||||
| Revenue Growth | 124.7% | 124.7% | -10.1% | 321.5% | — |
| EPS Growth | 35.7% | 35.7% | 34.3% | 5.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.61 → -1.04
Residual
+0.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.